ROIVANT SCIENCES LTD. Purchase Obligation, to be Paid, Year Four
ROIVANT SCIENCES LTD. (ROIV) had Purchase Obligation, to be Paid, Year Four of $14.00 million as of 2025-12-31, per its 10-Q filed 2026-02-06.
Financial Statements › Notes › Commitment and Contingencies › Purchase Obligation, Fiscal Year Maturity
us-gaap:PurchaseObligationDueInFourthYear · last filed 2026-02-06
- 2025-12-31: Purchase Obligation, to be Paid, Year Four $14.00M.
- 2025-09-30: Purchase Obligation, to be Paid, Year Four $14.00M.
| Period end | Purchase Obligation, to be Paid, Year Four |
|---|---|
| 2025-12-31 | $14.00M 10-Q · filed 2026-02-06 |
| 2025-09-30 | $14.00M 10-Q · filed 2025-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |